| INTRODUC TI ON
Uveal melanoma (UM) is the most common eye cancer in adults, affecting approximately six to seven individuals per million each year in Northern America, United Kingdom, and Australia (Chang, Karnell, & Menck, 1998; McLaughlin et al., 2005; Vajdic et al., 2003) .
The tumor arises from melanocytes within the uveal tract, with more than 90% of cases involving the choroid and the remainder affecting the iris and ciliary body (McLaughlin et al., 2005) . Despite favorable outcomes after local tumor control with either surgery or radiation therapy, up to 50% of patients develop distant metastatic disease (Kujala, Makitie, & Kivela, 2003) , with over 90% of metastases occurring in the liver (COMS, 2001) . Systemic chemotherapy, either as monotherapy or combination therapy, has shown limited activity in metastatic UM with no benefit in overall survival (Augsburger, 2009; Leyvraz et al., 2014; Pingpank et al., 2010) . Liver-directed therapies, including radioembolization with Yttrium-90, have produced some improvements in response rates that have not yet translated to survival benefits (Gonsalves et al., 2011; Klingenstein, Haug, Zech, & Schaller, 2013) , and a prospective clinical trial using Yttrium-90 radioembolization with immunotherapy in a selective cohort is currently recruiting (NCT02913417).
There have been significant improvements in the outcome of patients with advanced cutaneous melanoma (CM) treated with immunotherapy and targeted therapies. In patients with metastatic UM, however, these new treatments have failed to improve overall survival (OS). In a recent retrospective study, patients with metastatic UM receiving immunotherapy showed a response rate (RR) of <5% and median OS of <8 months (Algazi et al., 2016) . Thus, patients with metastatic UM continue to have a very poor prognosis with a 6-month progression-free survival (PFS) rate of 25% and 1-year OS rate of 40% (Khoja, Atenafu, & Joshua, 2016 ).
CM and UM share several host risk factors, including fair skin, light eye pigmentation, inability to tan, freckles, and naevi (Weis, Shah, Lajous, Shields, & Shields, 2006 , 2009 . Despite this, the genetic and signaling profiles of CM and UM are distinct. UM lacks mutations typically associated with CM (i.e., BRAF, NRAS, NF1, and TERT mutations), shows no enrichment in UV-induced C>T transitions at pyrimidine dimers, and has a low mutation burden (mean of 0.5 mutations per Mb in UM (Johansson et al., 2016) , compared to 17 mutations per Mb in CM (Akbani et al., 2015) ). Germ line risk factors also differ, with germ line mutations inactivating the deubiquitinating enzyme BRCA1-associated protein-1 (BAP1) predominantly found in patients with UM (Abdel-Rahman et al., 2011; Aoude et al., 2013) . Families with germ line BAP1 alterations are also at high risk of developing many other malignancies, including CM (1/193 probands from CM-prone families carry BAP1 mutations, Njauw et al., 2012) , renal cell carcinoma, meningioma, mesothelioma, and basal cell carcinoma (Abdel-Rahman et al., 2011; Testa et al., 2011; Wadt et al., 2015) .
Clinical features such as tumor size, tumor location, and histopathological factors (i.e., cell type, mitotic activity, and presence of extrascleral extension) are associated with metastatic risk, although the most accurate prognostic information for UM is based on cytogenetic and molecular profiling Singh, Shields, & Shields, 2001 ). UM can be accurately stratified into low/intermediate-and high-risk prognostic classes using a validated and patented 12-gene transcriptomic signature (DecisionDx-UM gene expression profile test) (Field & Harbour, 2014; Harbour, 2014) . Class 1A/1B tumors retain a differentiated melanocytic phenotype and are less aggressive, more immunogenic, and rarely metastasize. Class 2 tumors exhibit a stem celllike, dedifferentiated phenotype, are highly aggressive, and commonly give rise to metastatic disease. The risk of metastasis over five years has been determined to be 2% for class 1A tumors, 21% for class 1B tumors, and 72% for class 2 tumors (Field & Harbour, 2014) . Importantly, recent analysis has confirmed that the genetic profile of UM will influence the risk of metastasis within these prognostic classes (Harbour, 2014) .
| G ENE TI C S OF U VE AL MEL ANOMA
Activation of G protein-coupled receptor (GPCR) signaling is central to early UM development and occurs in almost all primary UM via hotspot mutations in GNAQ, GNA11, CYSLTR2, or PLCB4. GNAQ and GNA11 encode the Gα q/11 nucleotide-binding subunits of heterotrimeric G proteins and are considered the major drivers of UM carcinogenesis (Table 1) . Mutually exclusive activating mutations in GNAQ/GNA11 occur in over 90% of UM and affect Gln209, and less frequently Arg183 to inhibit GTPase activity and maintain G proteins in a constitutively active state. The cysteinyl leukotriene receptor 2 (CYSLTR2) gene encodes the CysLT 2 R GPCR (Moore et al., 2016) and is constitutively activated via a Leu129Gln mutation in 4% of primary
TA B L E 1 Driver mutations in uveal melanoma

Gene
Description Function
Uveal melanoma-associated mutations UM. Phospholipase C, β4 (PLCβ4), activates signaling downstream of GPCR by directly binding Gα q and is activated in an additional 2.5%-4% of primary UM by Asp630Tyr/Phe/Asn mutations (Robertson et al., 2017) . Interestingly, one of 28 UM samples had a novel mutation in another phospholipase, phospholipase C, β3 (PLCβ3), which signals downstream of GNAQ and GNA11 (Johansson et al., 2016) .
Metastatic risk and prognosis
GNAQ
In the recent UM project of The Cancer Genome Atlas, only 2/80 primary UM were wild type for GNAQ, GNA11, CYSLTR2, and PLCB4 (Robertson et al., 2017) . Table 1 ). BAP1 encodes a nuclear ubiquitin hydrolase with multiple nuclear and cytoplasmic substrates, including the BRCA1-associated RING domain protein-1 (BARD1), histone H2A, the host cell factor 1, Yin-Yang1 transcription factors, and the calcium channel IP3R3 (Bononi et al., 2017) .
Consistent with these targets, BAP1 regulates DNA repair, transcription, chromatin structure, cell differentiation, and cell death (Tyagi, Chabes, Wysocka, & Herr, 2007) . Given the role of BAP1 in DNA repair, its loss in UM may contribute to the acquisition of later onset cytogenetic aberrations, including 8q copy number gains (Robertson et al., 2017) . Several other copy number alterations occur in UM, and gains in chromosome 6p (contains the CNKSR3 gene which encodes membrane-associated guanylate kinase-interacting protein-like 1) correlate with extended metastasis-free survival and improved patient survival, even in the presence of chromosome 3 loss or 8q gain ( Figure 1 ) (Lake et al., 2013; White, Chambers, Courtright, Chang, & Horsman, 1998) . 
| ON COG ENIC S IG NALING
The discovery of key molecular drivers in UM that are mutually exclusive (i.e., mutations in GNAQ, GNA11, PLCB4, and CYSLTR2 do not coexist in UM, and alterations in BAP1, SF3B1, SRSF2, and EIF1AX
are also mutually exclusive) suggests that UM shares a limited set of core and potentially actionable signaling pathways (Moore et al., 2016) . One such pathway involves the transfer of signals from the GPCR CysLT 2 R to GNAQ and GNA11 and then to downstream effectors, such as phospholipase C-β (PLCβ), protein kinase C (PKC), ADP-ribosylation factor 6 (ARF6), and β-catenin. These signaling changes stimulate multiple, diverse pathways, including the mitogen-activated protein kinase (MAPK) cascade, the PI3K/AKT survival network, and Rho GTPase signaling ( Figure 2 ).
The precise contribution of these downstream signaling pathways in UM initiation and progression remains unclear. For instance, although ARF6 acts as a proximal node of oncogenic GNAQ signaling and contributes to activation of PLCβ, PKC, Rho GTPases, and MAPK signaling pathways (Yoo et al., 2016) , no ARF6 mutations have been discovered in UM, whereas mutations in PLCβ4 and PLCβ3 occur in 2.5%-4% of UM (Robertson et al., 2017) . The PLC mutations specifically activate the PLC-PKC-MAPK node, highlighting the potential importance of this canonical downstream pathway in UM.
The functional role of the driver oncogenes in UM is also modulated by late-onset, secondary alterations. For instance, GNAQmediated activation of the PKC-MAPK pathway is enhanced in UM with chromosome 3 monosomy and BAP1 loss (Robertson et al., 2017) . Similarly, whereas CysLT 2 R activation promotes the expression of the melanocytic differentiation-specific genes (MITF, TYR, DCT, and TRPM1) (Moore et al., 2016) , this transcription program is downregulated in the presence of chromosome 3 monosomy F I G U R E 1 Acquisition of driver and secondary genetic alterations drive uveal melanoma (UM) development and progression. The sequential acquisition of genetic changes (highlighted within the vertical arrows) leads to distinct genetic profiles that reflect the risk of UM metastases. Adapted from Robertson et al., 2017; Royer-Bertrand et al. (2016) [Colour figure can be viewed at wileyonlinelibrary.com]
and altered BAP1 (Matatall et al., 2013) . Further, poor prognostic UM (lacking BAP1 and chromosome 3) can be subdivided into two subsets with distinct cellular signaling profiles, the first profile is indicative of hypoxia, MYC transcription factor signaling, and active DNA damage response, and the second associated with higher activity of the FOXA1 and FOXM1 transcription factors and elevated MAPK and AKT activity (Robertson et al., 2017) . Suppression of the FOXM1-regulated transcriptional network with the bromodomain inhibitor JQ1 was recently shown to induce potent UM cell death in vitro (Bailey et al., 2018) . UM with chromosome 8q gains is also thought to rely on elevated MYC transcription factor activity (MYC is localized on 8q24.21), although PARADIGM pathway analysis revealed that MYC/MAX transcriptional activity is similar in UM with or without 8q gains. Instead, transcriptional targets of the MYC/ MAX/MIZ transcriptional complex are elevated in UM with chromosome 8q gains, suggesting that MYC activity is regulated via additional mechanisms (Robertson et al., 2017) .
Several other signaling pathways, not directly related to the initiating oncogenic drivers, are also critical in UM progression. The retinoblastoma (Rb) and p53 pathways are altered in UM; however, mutations in the genes encoding for these proteins are rare (Brantley & Harbour, 2000; Chana et al., 1999; Sun, Tran, Worley, Delston, & Harbour, 2005) . Cyclin D1 is a critical regulator for cell cycle progression through G1 to S phase, and cyclin D1 positivity was identified as an independent prognostic factor and associated with more aggressive UM (Coupland et al., 2000) . Overexpression of cyclin D1
and CDKN2A promoter methylation are thought to contribute to the constitutive hyperphosphorylation and functional inactivation of the Rb protein, and overexpression of murine double minute 2 (MDM2) is thought to be responsible for inactivation of p53 thus allowing tumor progression (Coupland et al., 2000; Van Der Velden et al., 2001 ).
| Mitogen-activated protein kinase signaling
The MAPK cascade is frequently elevated in UM, with 45%-86% of activity (Aiba et al., 2004; Zheng et al., 2005) . RasGRP3 transcription is also increased in a PKC-dependent manner in response to GNAQ activation in UM (Chen et al., 2017; Moore et al., 2018 uveal melanocytes expressing GNAQ Q209P displayed phosphorylated ERK1/2 (Mouti et al., 2016) . These data suggest that early acquisition of hyperactive GNAQ/GNA11 mutations may promote the transient activation of MAPK consistent with the rapid, yet transient activation of PLC (Ross, 2011) . Thus, the sustained activation of MAPK in UM may require secondary genetic alterations that occur during disease progression.
| PI3K/AKT pathway
The PI3K/AKT pathway is a critical regulator of cell growth and survival and is activated in at least 50% of UMs, often in the presence of MAPK hyperactivity (Populo, Soares, Rocha, Silva, & Lopes, 2010; Saraiva, Caissie, Segal, Edelstein, & Burnier, 2005) (Figure 2 ).
The PI3K/AKT cascade is not stimulated by GNAQ/GNA11 activity (Griewank et al., 2012; Pópulo et al., 2013) is required for the phosphorylation and activation of AKT at the plasma membrane (Stahl et al., 2003) and UM survival (Babchia, Calipel, Mouriaux, Faussat, & Mascarelli, 2010) . PI3K/AKT signaling cooperates with the proliferative MAPK network in promoting uveal melanomagenesis, and the combined inhibition of both pathways was required to induce apoptosis in GNAQ/GNA11-mutant UM cells .
| Rho GTPase signaling
Gα q/11 signaling also promotes the activation of the Rho GTPases, RhoA, and Rac1, and this leads to gene expression changes, actin cytoskeletal remodeling, and cell growth. Gα q/11 stimulates Rho GTPase activity by directly binding multiple members of the Rho guanine nucleotide exchange factor (RhoGEF) family, including TRIO and p63RhoGEF (Debant et al., 1996; Lutz et al., 2005) . TRIO is widely expressed and contains two GEF domains which may enable Gα q/11 linked GPCR to simultaneously activate RhoA and Rac1. 
| ADP-ribosylation factor 6 (ARF6)
The small GTPase ADP-ribosylation factor ARF6 is an immediate downstream effector of GNAQ oncogenic signaling (Figure 2 ).
Oncogenic GNAQ forms a complex with the ARF-guanine nucleotide exchange factor GEP100 to activate ARF6, which directs the redistribution of cell surface GNAQ to active signaling vesicles within the cytoplasm. Consequently, the knockdown of GNAQ, ARF6, or GEP100 in GNAQ/GNA11-mutant UM cell lines each diminished the activation of PLC, Rho, Rac, MAPK, β-catenin, and YAP (Yoo et al., 2016) . ARF6 is an important mediator of proliferation, invasion, and metastasis in many tumor types (Grossmann et al., 2013; Hu et al., 2009; Li et al., 2017; Manabe et al., 2008) , and inhibition of ARF6 with a small molecule inhibitor diminished proliferation and tumorigenesis in a xenograft model of UM (Yoo et al., 2016) . Epidermal growth factor receptor (EGFR) expression has also been reported in UM, although it appears that EGFR immunoreactivity is generally low in UM (23%-30%) and may have been overestimated due to EGFR-positive macrophages (Mallikarjuna, Pushparaj, Biswas, & Krishnakumar, 2007; Scholes, Hagan, Hiscott, Damato, & Grierson, 2001 ). Abundant EGFR overexpression has only been detected in two established UM cell lines, Mel285 and Mel290 (Amaro et al., 2013) , and the origin of these cell lines has been queried as they lack several genetic features common to UM (i.e., both are wild type for GNAQ, GNA11, EIF1AX, SF3B1, and BAP1), they do not express the melanocytic marker Melan-A, and Mel285 does not carry the GNAQ mutation identified in the original UM (reviewed in, Jager, Magner, Ksander, & Dubovy, 2016) . Recent data also confirm that UM cell lines generally do not express EGFR protein, and EGFR transcript expression is much lower in UM than in other cancer types, including CM (Bailey et al., 2018) . Nevertheless, UM often displays concurrent overexpression of several RTKs which can stimulate multiple downstream signaling cascades, including the MAPK and PI3K/AKT pathways ( Figure 2 ).
| Receptor tyrosine kinases
The mechanism of RTK activation in UM is not well understood but appears to involve autocrine receptor stimulation (AbdelRahman et al., 2011) rather than activating RTK gene mutations or amplifications. The inhibition of individual RTKs does not appear sufficient to prevent the growth of UM in vivo (Gardner et al., 2014) , and this is likely due to the oncogenic signaling driven by mutant Gα q/11 , PLCβ, and CysLT 2 R. Nevertheless, RTKs may contribute to invasion and metastasis, and simultaneous RTK activation may cooperate in promoting UM progression. For instance, c-MET inhibition suppressed UM cell migration in vitro and prevented UM from forming macroscopic metastatic disease in a xenograft mouse model (Surriga et al., 2013) . Further, coinhibition of c-MET and the MAPK effectors MEK1/2 diminished MAPK and PI3K signaling and induced potent cell death in human UM ex vivo (Cheng et al., 2017) . 3.1% compared to dacarbazine (0%) with no statistically significant benefit in OS (Carvajal et al., 2018) .
| Therapeutic targeting
Activation of PKC has been implicated as a major driver of MAPK activity in UM, and PKC inhibitor monotherapy has shown clinical activity. A preclinical study using the pan PKC inhibitor AEB071 (sotrastaurin), which inhibits the classical (α, β1) and novel isoforms of PKC (δ, ε, η, and θ) (Evenou et al., 2009) , decreased cell viability in GNAQ/GNA11-mutant UM cell lines, and this was associated with the downregulation of PKC/MAPK and PKC/NFκΒ pathways (Wu, Li, Zhu, Fletcher, & Hodi, 2012) . In a phase I clinical trial, nearly half of 118 patients treated with AEB071 achieved stable disease (47%) and one patient achieved partial response. The ongoing need for effective therapies in metastatic UM has seen an increased interest in combination targeted therapies. For instance, preclinical data showed strong synergy between PKC and MEK inhibition in GNAQ/GNA11-mutant UM cell lines (Chen et al., 2014) , and this has led to a phase Ib/II clinical trial using the MEK inhibitor binimetinib combined with the PKC inhibitor AEB071 which is waiting on analysis (NCT01801358). AEB071 has also been combined with a PI3K inhibitor (BYL719), this combination showed synergistic effect in preclinical UM models ( BAP1 promotes cellular recovery after DNA damage (Yu, Pak et al., 2014) and is inactivated in various cancers including UM.
BAP1 loss in class 1 UM cells induced H2A hyperubiquitination, loss of melanocytic differentiation, and acquisition of class 2 gene profile, and this can be reversed by inhibition of histone deacetylases (HDACs), which reprogram class 2 UM cells to a more differentiated class 1 phenotype in vivo (Harbour et al., 2010; Landreville et al., 2012) . Preclinical data support a current phase II trial evaluating the HDAC inhibitor, vorinostat, in patients with metastatic UM (NCT01587352).
The tropism of metastatic UM to the liver in 90% of cases suggests that hepatic growth factors may contribute to tumorigenesis.
This has been confirmed for the insulin-like growth factor-1, which is primarily produced in the liver and promotes UM migration, invasion, and proliferation (Wu, Zhou et al., 2012) . IIGF-1R has also been found to be overexpressed in UM with high metastatic risk (AllEricsson et al., 2002; Economou et al., 2008; Wu, Zhou et al., 2012) .
A recent phase II trial combining everolimus (mTOR inhibitor) and pasireotide (IGF-1R inhibitor), however, showed limited clinical benefit (Shoushtari, Ong et al., 2016) . Inhibiting c-MET, the membrane receptor for hepatocyte growth factor, with the inhibitor crizotinib, limited progression of UM in vivo and in vitro (Surriga et al., 2013) .
More recently, combination of c-MET inhibitor LY2801653 and MEK inhibitor has shown significant activity in preclinical models (Cheng et al., 2017) .
A number of other selective molecular therapies have also been tested in UM phase I/II clinical trials. Up to 75% of metastatic UM have been shown to express the c-Kit receptor tyrosine kinase, but activation-related mutations of c-Kit have not been identified (Mouriaux et al., 2003) . In earlier studies, patients with c-Kit expressing UM have been trialed with imatinib, a c-Kit inhibitor (Hofmann, Kauczok-Vetter, Houben, & Becker, 2009; Nathan et al., 2012; Penel et al., 2008) . Multitargeted tyrosine kinase inhibitors such as sunitinib and sorafenib have also been tested in phase II trials (Bhatia et al., 2012; Mahipal et al., 2012; Mouriaux et al., 2016; Sacco et al., 2013) , but none of these inhibitors have shown clinical benefit. Bevacizumab and aflibercept, which inhibit VEGF, have also failed to show any significant clinical benefit (PipernoNeumann et al., 2016; Tarhini et al., 2011) . Cabozantinib, a nonspecific MET and tyrosine kinase inhibitor, was tested in a phase II trial, and the UM cohort showed 61% of patients (14/23) achieved stable disease at week 12, with median PFS of 4.8 months and median OS of 12.6 months (Daud et al., 2017) . Thus, overexpression of RTKs in UM is not predictive of clinical response to RTK inhibition, and this presumably reflects the underlying mutation profile (i.e., GNAQ/GNA11, PLCB, and CYSLTR2) and oncogenic signaling activity present in each tumor.
Several new inhibitors have also shown promise in preclinical models of UM. For instance, verteporfin disrupts the interaction between YAP and TEAD4 transcription factors in UM, and this leads to the suppression of proliferation, migration, and invasion while promoting UM cell death via apoptosis (Ma, Liu, & Pan, 2016; Yu, Luo et al., 2014) . ARF6 inhibition with the small molecule inhibitor NAV2729 reduces the growth of GNAQ-dependent UM in vitro and in vivo (Yoo et al., 2016) . Genetic ablation of Ric-8A, a molecular chaperone that selectively folds and stabilizes Gαq/i/13 subunits, was also shown to suppress tumorigenesis mediated by GNAQ Q209L (Patel & Tall, 2016) . Hypoxia-inducible factors (HIFs) are transcription factors regulating expression of various genes involved in glycolysis and angiogenesis allowing cancer to survive in a hypoxic environment (Burroughs et al., 2013) . This includes VEGF, C-X-C chemokine receptor type 4, hepatocyte growth factor and MET, signal transducer and activator of transcription 3 (STAT3), and matrix metalloproteinases 2 and matrix metalloproteinases 9. HIFs have been found to be overexpressed in UM, and targeting hypoxia-mediated pathways have been identified as a potential therapy (Mouriaux et al., 2014) . KCN1, a novel small molecule, was able to suppress protein expression of p-MET, p-MAPK, and p-STAT3 in preclinical models to suggest a potential therapeutic agent in metastatic UM (Zhang, Yang, Kaluz, Van Meir, & Grossniklaus, 2013) . More recently, RasGRP3, which is transcriptionally upregulated by oncogenic Gα q/11 signaling and is activated via PKC-dependent phosphorylation and PKC-independent DAG-mediated membrane recruitment, has been identified as a potential therapeutic target (Figure 2 ) (Chen et al., 2017; Moore et al., 2018 
| Immunotherapy
Immune checkpoint inhibitors have now become the standard therapy in metastatic CM. The majority of phase III clinical trials published have excluded patients with metastatic UM, and there is lack of information on efficacy of immunotherapy in this cohort.
Although it is beyond the scope of this article to review available clinical data on immune checkpoint therapy trials in metastatic UM, to date, these treatments have shown limited activity. Based on six retrospective studies, ipilimumab, a monoclonal antibody targeting CTLA-4, has shown response rates ranging from 0% to 5% and median OS ranging from 5.2 to 10.3 months (Danielli et al., 2012; Deo, 2014; Kelderman et al., 2013; Khattak, Fisher, Hughes, Gore, & Larkin, 2013; Luke et al., 2013; Maio et al., 2013) . Further, the largest retrospective study using anti-PD-1 and anti-PD-L1 immunotherapy in 58 patients with metastatic UM showed an objective RR of only 3.6%, median PFS of 2.6 months, and median OS of 7.6 months (Algazi et al., 2016) . To date, immunotherapy has shown less activity in metastatic UM compared to advanced CM. Potential reasons for such poor response include UM having a very low mutational load and the majority of patients displaying metastases to the liver which is an immunosuppressive organ (Krauthammer et al., 2012; McKenna & Chen, 2010) . There are currently clinical trials underway using immunotherapy as monotherapy (NCT02359851, NCT02626962) and in combination (NCT01585194) in metastatic UM.
| CON CLUS IONS
Detailed understanding of the genetic and molecular signals contributing to UM has provided an unprecedented opportunity for the rational design of new therapies. Unfortunately, promising targets and single-agent response data in preclinical models of UM have not translated into improvement in patient survival, with most singleagent therapies showing limited efficacy and minimal improvement in OS. This is not surprising considering the complex downstream signaling changes that occur in response to the initiating driver mutations in UM, but also highlights the complex genetic and signaling profile of metastatic UM. There is, therefore, a critical need for a combinatorial therapeutic approach that requires accurate and reproducible drug selection using better preclinical models. These models need to incorporate a broad range of patient-derived xenografts that represent the diverse genetic, molecular, and prognostic classes of UM. The success of immunotherapy in treating CM has also failed to improve UM patient outcomes, and we still await further refinements in the development of combined immune checkpoint inhibitor therapy. 
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